Business Context and Reporting Period
This Form 8-K covers events for Alnylam Pharmaceuticals, Inc. occurring on May 2, 2017 (Annual Meeting) and May 5, 2017 (Financial Results Announcement). The filing reports on the 2017 Annual Meeting of Stockholders and references the announcement of financial results for the quarter ended March 31, 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Corporate Actions
The primary material events reported are the outcomes of the Annual Meeting of Stockholders held on May 2, 2017. As of the record date (March 10, 2017), 86,052,558 shares of common stock were issued and outstanding.
- Director Elections: Stockholders re-elected four Class I directors (Michael W. Bonney, John M. Maraganore, Paul R. Schimmel, and Phillip A. Sharp). Notably, Dr. Phillip A. Sharp received a significant number of votes against (6,877,420) compared to the other nominees.
- Compensation Plans: Stockholders approved the Second Amended and Restated 2009 Stock Incentive Plan and the Amended and Restated 2004 Employee Stock Purchase Plan.
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation and recommended an annual frequency for future advisory votes.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2017.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information regarding financial results (Item 2.02) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act. Investors are directed to the press release (Exhibit 99.1) for operational details.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 5, 2017) for actual Q1 2017 financial figures (revenue, net loss, cash position).
- Verify the specific reasons for the high number of "Against" votes for director Phillip A. Sharp (approx. 9.4% of votes cast).
- Confirm the details of the approved Stock Incentive Plan and Employee Stock Purchase Plan to assess potential dilution.
- Check subsequent filings for the full text of the Q1 2017 earnings call transcript for management commentary on pipeline progress and cash burn.